Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Samuel C. Blackman Insider Profile
4 Followers
Samuel C. Blackman, HEAD OF R&D at Day One Biopharmaceuticals, holds 2.03M shares in Day One Biopharmaceuticals (Ticker: DAWN).
Samuel C. Blackman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Samuel C. Blackman's holdings
Insider Roles
HEAD OF R&D
Roles that Samuel C. Blackman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Samuel C. Blackman
Samuel C. Blackman's Trading History
List of latest transactions for each holding click on a transaction to see Samuel C. Blackman's performance on stock
You May Also Like
Samuel C. Blackman insider profile FAQ
What is the percentage of profitable transactions made by Samuel C. Blackman?
The percentage of profitable transactions made by Samuel C. Blackman is ―.
What is the average return per transaction made by Samuel C. Blackman?
The average return per transaction made by Samuel C. Blackman is ―.
What stocks does Samuel C. Blackman hold?
Samuel C. Blackman holds: DAWN stocks.
What was Samuel C. Blackman’s latest transaction?
Samuel C. Blackman latest transaction was an Uninformative Sell of $399.30K.
What was Samuel C. Blackman's most profitable transaction?
Samuel C. Blackman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Samuel C. Blackman's role in Day One Biopharmaceuticals?
Samuel C. Blackman's role in Day One Biopharmaceuticals is HEAD OF R&D.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.